

Supplemental Table 3. Patient characteristics of unweighted and weighted population

Characteristic	Overall, N = 222	Unweighted population ^a			Weighted population ^b		
		Eligible, N = 138	Ineligible, N = 84	SMD	Eligible	Ineligible	SMD
Age at baseline, year (mean [SD])	71.7 (9.4)	71.5 (8.9)	72.2 (10.2)	0.08	71.5 (8.6)	72.7 (10.0)	0.13
Sex				0.07			0.06
Male	165 (74.3)	101 (73.2)	64 (76.2)		74.7	77.1	
Female	57 (25.7)	37 (26.8)	20 (23.8)		25.3	22.9	
ECOG performance status				0.38			0.05
0	105 (47.3)	75 (54.3)	30 (35.7)		51.4	53.9	
1 or more	117 (52.7)	63 (45.7)	54 (64.3)		48.6	46.1	
Body mass index, kg/m ² (mean [SD])	21.9 (3.6)	22.3 (3.7)	21.2 (3.2)	0.34	21.8 (3.7)	21.8 (3.2)	0.02
Smoking status				0.18			0.04
Former or current	126 (56.8)	83 (60.1)	43 (51.2)		56.2	54.2	
Never	96 (43.2)	55 (39.9)	41 (48.8)		43.8	45.8	
Previous radical surgery	138 (62.2)	97 (70.3)	41 (48.8)	0.45	62.5	58.4	0.08
Primary location of tumor				0.22			0.06
Lower tract	118 (53.2)	79 (57.2)	39 (46.4)		52.7	49.8	
Upper tract	104 (46.8)	59 (42.8)	45 (53.6)		47.3	50.2	
Location of metastasis				0.32			0.03
LN and visceral metastasis	87 (39.2)	46 (33.3)	41 (48.8)		40.2	38	
LN or visceral metastasis	135 (60.8)	92 (66.7)	43 (51.2)		59.8	62	
Liver metastasis	43 (19.4)	17 (12.3)	26 (31.0)	0.46	16.9	21.5	0.12
Platinum				0.48			0.03
Other platinum	70 (31.5)	32 (23.2)	38 (45.2)		35.1	33.8	
Cisplatin	152 (68.5)	106 (76.8)	46 (54.8)		64.9	66.2	
Most recent chemotherapy				0.4			0.06
Perioperative	54 (24.3)	42 (30.4)	12 (14.3)		22.9	20.5	
Salvage	168 (75.7)	96 (69.6)	72 (85.7)		77.1	79.5	
Concomitant proton pump inhibitor use	91 (41.0)	45 (32.6)	46 (54.8)	0.46	38.8	37.5	0.03
Previous antibiotic use	39 (17.6)	18 (13.0)	21 (25.0)	0.31	18.9	23.7	0.12
Baseline neutrophil-to-lymphocyte ratio (mean [SD])	4.5 (3.8)	4.0 (3.3)	5.3 (4.4)	0.32	4.7 (4.5)	4.8 (3.7)	0.02
Bajorin risk score				0.39			0.05
0	103 (46.4)	74 (53.6)	29 (34.5)		46.3	48.9	
1 to 2	119 (53.6)	64 (46.4)	55 (65.5)		53.7	51.1	
Without progression following chemotherapy	58 (26.1)	37 (26.8)	21 (25.0)	0.04	27.3	29.1	0.04

SMD; standardized mean difference, ECOG; eastern cooperative oncology group, LN; lymph node, SD; standard deviation

a: Data are presented as number (percentage) of patients

b: Data are presented as percentage of patients